Profile data is unavailable for this security.
About the company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
- Revenue in EUR (TTM)0.00
- Net income in EUR-147.74m
- Incorporated2013
- Employees40.00
- LocationAbivax SA7-11 Boulevard HaussmannPARIS 75009FranceFRA
- Phone+33 153830963
- Fax+33 494279261
- Websitehttps://www.abivax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cellectis SA | 11.17m | -72.23m | 145.81m | 235.00 | -- | 1.74 | -- | 13.05 | -1.22 | -1.03 | 0.1639 | 1.16 | 0.04 | -- | 1.41 | 47,550.21 | -27.82 | -24.08 | -42.40 | -30.69 | -- | -64.64 | -694.72 | -308.24 | -- | -- | 0.552 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 166.03m | 55.00 | -- | 7.15 | -- | 74.55 | -1.18 | -1.18 | 0.1138 | 1.06 | 0.0256 | -- | 3.22 | 40,490.91 | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -55.59 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Eurobio Scientific SA | 130.00m | 4.84m | 170.13m | 137.00 | 38.47 | 1.04 | 9.46 | 1.31 | 0.4315 | 0.4315 | 11.59 | 16.02 | 0.4018 | 3.19 | 4.31 | 948,927.00 | 1.49 | 16.91 | 1.80 | 21.53 | 47.11 | 50.95 | 3.72 | 23.34 | 2.32 | 4.03 | 0.3666 | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
| Innate Pharma SA | 51.90m | -7.57m | 171.65m | 179.00 | -- | 3.30 | -- | 3.31 | -0.0939 | -0.0939 | 0.6451 | 0.642 | 0.2648 | -- | 5.67 | 289,949.70 | -3.86 | -8.83 | -4.87 | -12.11 | 94.50 | 93.17 | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Sensorion SA | 0.00 | -22.06m | 194.12m | 50.00 | -- | 3.63 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| Genfit SA | 38.18m | -28.89m | 202.37m | 159.00 | -- | 2.97 | -- | 5.30 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Nanobiotix SA | 30.06m | -39.70m | 225.11m | 102.00 | -- | -- | -- | 7.49 | -1.10 | -1.10 | 0.814 | -0.0391 | 0.3912 | -- | 19.59 | 294,686.30 | -51.67 | -54.11 | -120.56 | -80.68 | -- | -- | -132.08 | -756.15 | -- | -1.98 | 1.04 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
| Valneva SE | 152.96m | -24.39m | 456.27m | 684.00 | -- | 2.41 | 8.92 | 2.98 | -0.1943 | -0.1943 | 1.10 | 1.36 | 0.2799 | 2.34 | 5.63 | 223,622.80 | -4.46 | -15.39 | -6.84 | -25.06 | 32.95 | 35.94 | -15.95 | -34.95 | 2.22 | -2.69 | 0.528 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Abivax SA | 0.00 | -147.74m | 709.97m | 40.00 | -- | 3.60 | -- | -- | -3.35 | -3.35 | 0.00 | 3.12 | 0.00 | -- | -- | 0.00 | -73.79 | -65.49 | -96.88 | -94.75 | -- | -- | -- | -- | -- | -8.05 | 0.2206 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
Data as of Jul 26 2024. Currency figures normalised to Abivax SA's reporting currency: Euro EUR
10.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 30 Sep 2023 | 2.68m | 4.25% |
| VHCP Management LLCas of 31 Dec 2023 | 2.61m | 4.15% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 761.00k | 1.21% |
| Pictet Asset Management SAas of 31 Mar 2024 | 174.76k | 0.28% |
| HSBC Global Asset Management (France) SAas of 31 May 2024 | 162.72k | 0.26% |
| Saint Olive Gestion SNCas of 29 Dec 2023 | 109.29k | 0.17% |
| LSP Advisory BVas of 31 Dec 2023 | 98.93k | 0.16% |
| BlackRock Fund Advisorsas of 03 Jul 2024 | 75.64k | 0.12% |
| CPR Asset Management SAas of 31 Mar 2024 | 73.06k | 0.12% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 61.73k | 0.10% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
